Abstract
MicroRNAs (miRNAs), which are highly conserved, non-coding endogenous RNA and nearly ~22 nucleotides (nt) in length, have been widely reported to play the crucial roles in a number of pathological processes, most notably cancer. Hitherto, accumulating evidence has demonstrated that miRNAs are involved in mediating several cancer-related pathways linked to Programmed cell death (PCD), indicating that miRNAs may function as the key regulators in apoptosis and autophagy of cancer. In this review, we present a brief outline of the discovery, biosynthetic pathway and regulatory mechanisms of miRNAs, and further elucidate how miRNAs can regulate apoptotic and autophagic pathways as oncogenes or tumor suppressor genes in cancer. Together, these inspiring findings would help cancer biologists and clinicians uncover the mysterious landscape of miRNAs, thereby ultimately harnessing the miRNA-targeted PCD pathways for future cancer therapeutics.
Keywords: Apoptosis, autophagy, cancer, MicroRNA (miRNA), Programmed Cell Death (PCD)
Current Chemical Biology
Title:MicroRNA Regulation of Programmed Cell Death Pathways in Cancer
Volume: 6 Issue: 1
Author(s): Miao Ming, Xu Zhao, Zi-yi Zhao, Bo Liu and Jin-ku Bao
Affiliation:
Keywords: Apoptosis, autophagy, cancer, MicroRNA (miRNA), Programmed Cell Death (PCD)
Abstract: MicroRNAs (miRNAs), which are highly conserved, non-coding endogenous RNA and nearly ~22 nucleotides (nt) in length, have been widely reported to play the crucial roles in a number of pathological processes, most notably cancer. Hitherto, accumulating evidence has demonstrated that miRNAs are involved in mediating several cancer-related pathways linked to Programmed cell death (PCD), indicating that miRNAs may function as the key regulators in apoptosis and autophagy of cancer. In this review, we present a brief outline of the discovery, biosynthetic pathway and regulatory mechanisms of miRNAs, and further elucidate how miRNAs can regulate apoptotic and autophagic pathways as oncogenes or tumor suppressor genes in cancer. Together, these inspiring findings would help cancer biologists and clinicians uncover the mysterious landscape of miRNAs, thereby ultimately harnessing the miRNA-targeted PCD pathways for future cancer therapeutics.
Export Options
About this article
Cite this article as:
Ming Miao, Zhao Xu, Zhao Zi-yi, Liu Bo and Bao Jin-ku, MicroRNA Regulation of Programmed Cell Death Pathways in Cancer, Current Chemical Biology 2012; 6 (1) . https://dx.doi.org/10.2174/2212796811206010053
DOI https://dx.doi.org/10.2174/2212796811206010053 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Overview of Notch Signaling in Adult Tissue Renewal and Maintenance
Current Alzheimer Research MicroRNA-34 Family, Mechanisms of Action in Cancer: A Review
Current Cancer Drug Targets Pyrrolo[2,1-c][1,4]benzodiazepine as a Scaffold for the Design and Synthesis of Anti- Tumour Drugs
Anti-Cancer Agents in Medicinal Chemistry Recent Clinical Trials of Cladribine in Hematological Malignancies and Autoimmune Disorders
Reviews on Recent Clinical Trials The Circulating Endothelial Cell in Cancer: Towards Marker and Target Identification
Current Pharmaceutical Design Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity
Current Drug Delivery Regulation of Cytokine Production by γδ T Cells
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Cancer-Specific Ligands Identified from Screening of Peptide-Display Libraries
Current Pharmaceutical Design Biological and Clinical Significance of Polymorphisms in NAD(P)H: Quinone Oxidoreductase 1 (NQO1)
Current Pharmacogenomics Mesenchymal Stromal Cells from Umbilical Cord Blood
Current Stem Cell Research & Therapy Anti-CD20 Antibody in Primary Sjogren's Syndrome Managemen
Current Pharmaceutical Biotechnology Modelling and Measuring Redox Cycling and Cytotoxicity of Quinones
Drug Metabolism Letters Survivin Modulators: An Updated Patent Review (2011 - 2015)
Recent Patents on Anti-Cancer Drug Discovery Novel Immunotherapies for Hematological Malignancies
Current Molecular Pharmacology Promotion of Apoptosis in Cancer Cells by Selective Purine-Derived Pharmacological CDK Inhibitors: One Outcome, Many Mechanisms
Current Pharmaceutical Design Monoclonal Antibodies, Bispecific Antibodies and Antibody-Drug Conjugates in Oncohematology
Recent Patents on Anti-Cancer Drug Discovery Modifications in the upper or Velbenamine Part of the Vinca Alkaloids have Major Implications for Tubulin Interacting Activities
Current Pharmaceutical Design Perspectives in Breast and Ovarian Cancer Chemotherapy by Nanomedicine Approach: Nanoformulations in Clinical Research
Current Medicinal Chemistry Somatic Mutations, Viral Integration and Epigenetic Modification in the Evolution of Hepatitis B Virus-Induced Hepatocellular Carcinoma
Current Genomics Death Receptor Signaling in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents